Literature DB >> 20428906

Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients.

Ignacio Blanco1, Nana Béritze, Mario Argüelles, Victoriano Cárcaba, Fernando Fernández, Sabina Janciauskiene, Katerina Oikonomopoulou, Frederick J de Serres, Enrique Fernández-Bustillo, Morley D Hollenberg.   

Abstract

Formalin-fixed, paraffin-embedded skin tissue sections were collected from a matched cohort of 63 fibromyalgia syndrome (FMS) patients and 49 volunteers from the general population with both alpha1-antitrypsin (AAT) normal and deficiency variants. These tissues were examined for the expression of the broad-spectrum inhibitor AAT, the serine proteinases elastase and tryptase, the proinflammatory cytokines MCP-1 and TNFα, the endothelium biomarker VEGF, and the inflammation/nociception-related receptor PAR(2). The most relevant finding of the study was a significantly increased number of mast cells (MCs) in the papillary dermis of all FMS patients (greater than or equal to five to 14 per microscopic high power field) compared to zero to one in controls (p < 0.001). MCs strongly stained with tryptase, AAT and PAR(2) antibodies, exhibited a spindle-like shape and were uniformly distributed around blood vessels and appendages. MCP-1 and VEGF expressed weak/moderate positivity in most samples, with a higher expression in controls than in FMS patients (p < 0.001 and 0.051, respectively). No differences in elastase and TNFα were found between both groups. Moreover, no histological differences were found between samples from AAT deficiency and normal AAT phenotypes. Our results indicate that FMS is a MC-associated condition. MCs are present in skin and mucosal surfaces throughout the human body, and are easily stimulated by a number of physical, psychological, and chemical triggers to degranulate, releasing several proinflammatory products which are able to generate nervous peripheral stimuli causing CNS hypersensitivity, local, and systemic symptoms. Our findings open new avenues of research on FMS mechanisms and will benefit the diagnosis of patients and the development of therapeutics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428906     DOI: 10.1007/s10067-010-1474-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies.

Authors:  W V Li; S B Kapadia; E Sonmez-Alpan; S H Swerdlow
Journal:  Mod Pathol       Date:  1996-10       Impact factor: 7.842

Review 2.  Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.

Authors:  H P Horny; P Valent
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

3.  Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways.

Authors:  K Dabbagh; G J Laurent; A Shock; P Leoni; J Papakrivopoulou; R C Chambers
Journal:  J Cell Physiol       Date:  2001-01       Impact factor: 6.384

4.  Increased expression of N-methyl-D-aspartate receptor subunit 2D in the skin of patients with fibromyalgia.

Authors:  Seong-Ho Kim; Tae Jung Jang; Il Soo Moon
Journal:  J Rheumatol       Date:  2006-04       Impact factor: 4.666

Review 5.  Evidence of involvement of central neural mechanisms in generating fibromyalgia pain.

Authors:  Roland Staud
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

6.  Low plasma levels of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency-related fibromyalgia.

Authors:  Ignacio Blanco; Sabina Janciauskiene; Izabela Nita; Enrique Fernández-Bustillo; Victoriano Cárcaba; César Gallo; Marlene Alvarez-Rico; Frederick de Serres; Nana Béridze
Journal:  Clin Rheumatol       Date:  2009-11-19       Impact factor: 2.980

7.  Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency.

Authors:  Ignacio Blanco; Hortensia Canto; Frederick Joseph de Serres; Enrique Fernandez-Bustillo; Maria Carmen Rodríguez
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

Review 8.  Functional somatic syndrome: how it could be relevant to rheumatologists.

Authors:  Kayo Masuko; Hiroshi Nakamura
Journal:  Mod Rheumatol       Date:  2007-06-20       Impact factor: 3.023

9.  Characteristic electron microscopic findings in the skin of patients with fibromyalgia--preliminary study.

Authors:  Seong-Ho Kim; Dong Hoon Kim; Dong-Ho Oh; Daniel J Clauw
Journal:  Clin Rheumatol       Date:  2008-03       Impact factor: 2.980

10.  Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia.

Authors:  Souzan Salemi; Janine Rethage; Uwe Wollina; Beat A Michel; Renate E Gay; Steffen Gay; Haiko Sprott
Journal:  J Rheumatol       Date:  2003-01       Impact factor: 4.666

View more
  27 in total

Review 1.  [Surgical interventions in patients with mast cell activation disease. Aspects relevant for surgery using the example of a cholecystectomy].

Authors:  B Sido; F L Dumoulin; J Homann; H-J Hertfelder; M Bollmann; G J Molderings
Journal:  Chirurg       Date:  2014-04       Impact factor: 0.955

Review 2.  Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms?

Authors:  S E Kim; L Chang
Journal:  Neurogastroenterol Motil       Date:  2012-08-02       Impact factor: 3.598

Review 3.  Fibromyalgia Pathogenesis and Treatment Options Update.

Authors:  Steven Chinn; William Caldwell; Karina Gritsenko
Journal:  Curr Pain Headache Rep       Date:  2016-04

4.  Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia.

Authors:  Kim D Jones; Terri Gelbart; Thomas C Whisenant; Jill Waalen; Tony S Mondala; David N Iklé; Daniel R Salomon; Robert M Bennett; Sunil M Kurian
Journal:  Clin Exp Rheumatol       Date:  2016-02-12       Impact factor: 4.473

5.  Excess risk of temporomandibular disorder associated with cigarette smoking in young adults.

Authors:  Anne E Sanders; William Maixner; Andrea G Nackley; Luda Diatchenko; Kunthel By; Vanessa E Miller; Gary D Slade
Journal:  J Pain       Date:  2011-10-26       Impact factor: 5.820

6.  Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial.

Authors:  Dennis C Ang; Janna Hilligoss; Timothy Stump
Journal:  Clin J Pain       Date:  2015-09       Impact factor: 3.442

Review 7.  Neurogenic inflammation in fibromyalgia.

Authors:  Geoffrey Littlejohn; Emma Guymer
Journal:  Semin Immunopathol       Date:  2018-03-19       Impact factor: 9.623

8.  Sleep Related Scratching: A Distinct Parasomnia?

Authors:  Gaurav Nigam; Muhammad Riaz; Shelley D Hershner; Cathy A Goldstein; Ronald D Chervin
Journal:  J Clin Sleep Med       Date:  2016-01       Impact factor: 4.062

9.  Dermatologic manifestations of fibromyalgia.

Authors:  Valerie Laniosz; David A Wetter; Desiree A Godar
Journal:  Clin Rheumatol       Date:  2014-01-14       Impact factor: 2.980

Review 10.  Fibromyalgia syndrome in need of effective treatments.

Authors:  Theoharis C Theoharides; Irene Tsilioni; Lauren Arbetman; Smaro Panagiotidou; Julia M Stewart; Rae M Gleason; Irwin J Russell
Journal:  J Pharmacol Exp Ther       Date:  2015-08-25       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.